| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.9 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.9 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | JQ-1:MK-0752 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.9 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |